Abstract:The interactions between polymers and the immune system remains poorly controlled. In some instances, the immune system can produce antibodies specific to polymer constituents. Indeed, roughly half of pe-gloticase patients without immunomodulation develop high titers of anti-PEG antibodies (APA) to the PEG polymers on pegloticase, which then quickly clear the drug from circulation and render the gout treatment ineffective. Here, using pegloticase as a model drug, we show that addition of high molecular weight (MW) free (unconjugated) PEG to pegloticase allows us to control the immunogenicity and mit-igates APA induction in mice. Compared to pegloticase mixed with saline, mice repeatedly dosed with pegloticase containing different MW or amount of free PEG possessed 4-to 12-fold lower anti-PEG IgG, and 6-to 10-fold lower anti-PEG IgM, after 3 rounds of pegloticase dosed every 2 weeks. The markedly reduced APA levels, together with competitive inhibition by free PEG, restored the prolonged circula-tion of pegloticase to levels observed in APA-naive animals. In contrast, mice with pegloticase-induced APA eliminated nearly all pegloticase from the circulation within just four hours post-injection. These re-sults support the growing literature demonstrating free PEG may effectively suppress drug-induced APA, which in turn may offer sustained therapeutic benefits without requiring broad immunomodulation. We also showed free PEG effectively blocked the PEGylated protein from binding with cells expressing PEG-specific B cell receptors. It provides a template of how we may be able to tune the interactions and immunogenicity of other polymer-modified therapeutics. Statement of significance A major challenge with engineering materials for drug delivery is their interactions with the immune system. For instance, our body can produce high levels of anti-PEG antibodies (APA). Unfortunately, the field currently lack tools to limit immunostimulation or overcome pre-existing anti-PEG antibodies, with-out using broad immunosuppression. Here, we showed that simply introducing free PEG into a clinical formulation of PEG-uricase can effectively limit induction of anti-PEG antibodies, and restore their pro-longed circulation upon repeated dosing. Our work offers a readily translatable method to safely and effectively restore the use PEG-drugs in patients with PEG-immunity, and provides a template to use unconjugated polymers with low immunogenicity to regulate interactions with the immune system for other polymer-modified therapeutics. (c) 2023 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Impact of Large Aggregated Uricases and PEG Diol on Accelerated Blood Clearance of PEGylated Canine Uricase

Characterization, efficacy, pharmacokinetics, and biodistribution of 5 kDa mPEG modified tetrameric canine uricase variant

A Novel Zwitterionic Copolymer with A Short Poly(Methyl Acrylic Acid) Block for Improving Both Conjugation and Separation Efficiency of A Protein Without Losing Its Bioactivity

Determination of PEGylation Homogeneity of Polyethylene Glycol-Modified Canine Uricase.

Species and Sex Differences in the Blood Clearance and Immunogenicity of PEGylated Uricase: A Comparative 26-Week Toxicity Study in Rats and Monkeys

Research on PEG Modification of Uricase

Research on N-Terminal Site-Specific PEGylated Uricase

Pegloticase Co-Administered with High MW Polyethylene Glycol Effectively Reduces PEG-immunogenicity and Restores Prolonged Circulation in Mouse

Accelerated blood clearance of PEGylated nanoparticles induced by PEG-based pharmaceutical excipients

Pharmacokinetics of Polyethylene Glycol-Modified Canine Uricase Following Single and Multiple Intravenous Injections in Cynomolgus Monkeys

High MW polyethylene glycol prolongs circulation of pegloticase in mice with anti-PEG antibodies

Effect of PEGylation on Properties of Uricase

PEGylation enhancement of pH stability of uricase via inhibitive tetramer dissociation.

Comparison of Modification of a Bacterial Uricase with N‐hydroxysuccinimide Esters of Succinate and Carbonate of Monomethoxyl Poly(ethylene Glycol)

Polyethylene Glycol‐Like Brush Polymer Conjugate of a Protein Drug Does Not Induce an Antipolymer Immune Response and Has Enhanced Pharmacokinetics than Its Polyethylene Glycol Counterpart

Immunogenicity-masking delivery of uricase against hyperuricemia and gout

Impact of anti-PEG antibody affinity on accelerated blood clearance of pegylated epoetin beta in mice

High-level production of uricase containing keto functional groups for site-specific PEGylation

Anti-PEG Scfv Corona Ameliorates Accelerated Blood Clearance Phenomenon of PEGylated Nanomedicines.

Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout

Accelerated Blood Clearance of Pegylated Liposomal Topotecan: Influence of Polyethylene Glycol Grafting Density and Animal Species.